நீல் மகாபத்ரா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from நீல் மகாபத்ரா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In நீல் மகாபத்ரா Today - Breaking & Trending Today
Snoop Dogg-backed Oxford Cannabinoid fluctuates in debut bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
CNBC that the money raised from the IPO will go towards developing four new drugs. “The key here is about getting cannabinoids into the hands of patients and the way you do that is through the drug development process,” Lucas said. “The medical cannabis, the problem with that is that physicians cannot prescribe it, so we want a drug product that we can get into the hands of physicians, into the hands of patients,” he added. Two of the company’s drug products will be heading into clinical trials following the IPO. According to Proactive Investors, OCT has a proprietary library of 93 cannabinoid derivatives. ....
Medical cannabis company backed by Snoop Dogg launches on London Stock Exchange winnipegsun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipegsun.com Daily Mail and Mail on Sunday newspapers.
Oxford Cannabinoid Technologies to list in London to further four drug development programs Oxford Cannabinoid Technologies Holdings Ltd s co-founder and executive chairman Neil Mahapatra talks to Proactive London ahead of their London initial public offer on Friday 21st May. The firm have raised £16.5mln to develop cannabis-based pain treatments and are expected to reach a valuation on listing of around £51mln. With the company focussed on medicines that mimic the painkilling effects of cannabis, it plans to use the funds raised in the IPO to help develop a portfolio of four drug candidates for approval as licensed pain medicines, with the aim of commercializing the company s first drug in 2027. ....